AARD — Aardvark Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1774857 ·
Last close
$1.15
Market Cap
$25.17M
52W High
$16.60
52W Low
$0.93
ADV30
1,206,783
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -19,717,000 | -19,186,000 | 64,800,000 | 60,335,000 | 7,193,000 |
| Jun 2026 | 0 | — | -15,084,000 | -14,387,000 | 81,460,000 | 73,849,000 | 6,663,000 |
| Mar 2026 | 0 | — | -22,464,000 | -21,588,000 | 98,590,000 | 62,436,000 | 11,604,000 |
| Dec 2025 | 0 | — | -18,704,000 | -17,598,000 | 117,181,000 | 47,051,000 | 10,548,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,408,000
Investing CF
$116,548,000
Financing CF
$711,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.21
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-151,893,000
Inventory
—
Receivables
—
ST Investments
$21,000
EBIT TTM
$-73,955,000
Pretax Income TTM
$-69,889,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -62,725,000 | -57,591,000 | 117,181,000 | 10,548,000 | 106,633,000 | -54,172,000 |
| Dec 2024 | 0 | -22,668,000 | -20,588,000 | 77,507,000 | 132,150,000 | -54,643,000 | -18,087,000 |
| Dec 2023 | 0 | -6,653,000 | -7,208,000 | 10,536,000 | 45,338,000 | -34,802,000 | -5,824,000 |
| Dec 2022 | 0 | -10,874,000 | -13,564,000 | 16,757,000 | 44,680,000 | -27,923,000 | -10,543,000 |
TTM Snapshot
Revenues TTM
$4,060,000
NetIncome TTM
$-69,889,000
OpCashFlow TTM
—
Assets (Latest)
$81,460,000
Forward EPS
$-2.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLCS | Cell Source, Inc. | $25.14M | $0.37 | — |
| BIOE | Bio Essence Corp | $25.29M | $0.47 | — |
| ABVC | ABVC BIOPHARMA, INC. | $25.36M | $0.94 | — |
| BETRF | BetterLife Pharma Inc. | $25.64M | $0.15 | — |
| ACET | Adicet Bio, Inc. | $26.03M | $2.78 | — |
News headlines (Yahoo Finance, 1h cache)
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-13 13:00 · Yahoo
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
2026-10-23 11:00 · Yahoo
Aardvark Therapeutics stock surges as FDA lifts clinical hold
2026-10-22 21:57 · Yahoo
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
2026-10-22 20:05 · Yahoo
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
2026-10-21 15:00 · Yahoo
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
2026-10-12 14:31 · Yahoo
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
2026-10-08 12:00 · Yahoo
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:05 · Yahoo
Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
2026-08-17 17:31 · Yahoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
2026-05-28 10:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.